Telehealth vs In-Person GLP-1 Care in the UK (October 2026)

01 · The short verdict

Which route suits whom

Choose telehealth if you meet the licensed criteria, want to start without waiting, and are comfortable managing a weekly injection at home. Choose in-person care if you have several health conditions, want a face-to-face examination, or are eligible for the NHS pathway and prefer to wait for it.

The NHS route is real but phased. Mounjaro is available on the NHS, NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions). Full rollout is expected to take years.⁴⁶ That is why many people who meet the licensed criteria choose regulated private treatment. See our guide to Mounjaro in primary care for more.

02 · Side by side

Telehealth vs in-person: comparison

The medicine itself is identical in both routes. In SURMOUNT-1 (2,539 adults), people on tirzepatide with diet and exercise lost on average 15% of body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, versus 3.1% with lifestyle changes alone. Trial averages do not predict your own result, and individual results vary.²

03 · How to decide

Decision factors that actually matter

Start with eligibility and safety, then convenience. A good provider of either kind will ask about your medical history, current medicines and goals, and will decline if treatment is unsuitable.

• Prescriber review: every order should be reviewed by a GPhC-registered prescriber, not an automated score.
• Ongoing review: look for monthly check-ins, dose titration and side-effect support.
• Regulation: verify the pharmacy on the GPhC register.
• Genuine supply: ask where the pens come from.
• Total cost: compare the pen price, any fees and whether there is a subscription.

You can see current Mounjaro pen prices and start a consultation, or browse all weight loss treatments.

Related guides: Agonisti glp 1 and Ozempil glp-1.

04 · What good telehealth looks like

What good telehealth looks like

Good telehealth is a regulated pharmacy with a real prescriber behind it. At EverydayMeds the free online consultation is a short health questionnaire with no obligation, reviewed by a GPhC-registered prescriber. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

Orders are dispensed by our registered pharmacy (GPhC 9012878).¹² Same-day dispatch applies when ordered by 3pm, with free next-day tracked delivery in temperature-controlled packaging. Mounjaro comes through official LillyDirect supply, with genuine KwikPens and all six doses in stock.

Warning signs include anyone offering to supply without a consultation or prescription, or selling unlicensed products. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme.⁷

05 · Where in-person care wins

Where in-person care wins

In-person care is stronger when you need physical examination, blood tests or coordination between several specialists. If you have complex conditions, your GP knows your full record and can weigh the treatment against everything else you take.

Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems, and either route should work through your full medical history and medicine list with you.¹¹³ Some GPs are cautious about prescribing because NHS access is phased and criteria are strict; that is a commissioning reality rather than a verdict on the medicine.

The weakness of in-person care is access: appointments, waiting and local variation. Our guide to financing weight loss injections covers payment options if cost is the barrier.

06 · Cost and payment

Cost and payment compared

Across the UK pharmacies we track, a Mounjaro pen costs between £143.96 and £339.00 per month depending on dose and provider (checked 10 October 2026). The gap between providers for the same dose ranges from £27 to £41.

At standard prices, a first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. A new customer's first order is £40 less, and every later order £25 less. We accept Visa, Mastercard, Klarna and pay-monthly options, with no subscription.

07 · Which medicine to ask about

Which medicine to ask about

The licensed weight-management injections are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg). Ozempic is licensed for type 2 diabetes, so private prescribing for weight loss is off-label, and a regulated UK pharmacy will not supply it for that purpose.

In the head-to-head SURMOUNT-5 trial, adults on tirzepatide lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4mg.¹⁵ In STEP 1, adults on Wegovy lost on average 14.9% over 68 weeks versus 2.4% on placebo.⁹ Both are licensed treatments; the choice depends on your health profile, tolerance and prescriber advice, not the headline number alone. See the Wegovy pen for the alternative.

Switching between them is prescriber-led: there is no licensed direct conversion, and two GLP-1 medicines must never run together.

08 · Cheaper alternatives and shortcuts

Cheaper alternatives and shortcuts

There is no tablet form of Mounjaro. Two GLP-1 tablets are now licensed in the UK: Wegovy tablets (approved by the MHRA in June 2026) and Foundayo (approved in August 2026). They are different medicines with their own eligibility checks, so ask a prescriber whether they suit you.

Orlistat blocks some dietary fat absorption and produces smaller average losses. 'Natural GLP-1' supplements such as berberine are not medicines, are not regulated for this use and have no comparable trial evidence; they are low-cost supplements with no clinical oversight.

Unlicensed 'research' peptides, compounded copies and stacking have no safety data and no regulated supply chain. Anything promising faster results outside a licensed pathway is the warning sign.